Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

Interventions

  • PROCEDURE management of therapy complications

Study Locations (20)

Florida

  • Lee Cancer Care of Lee Memorial Health System — Fort Myers
  • Nemours Children's Clinic — Jacksonville
  • University of Miami Sylvester Comprehensive Cancer Center - Miami — Miami
  • Florida Hospital Cancer Institute at Florida Hospital Orlando — Orlando
  • Nemours Children's Clinic - Orlando — Orlando
  • Nemours Children's Clinic - Pensacola — Pensacola
  • All Children's Hospital — St. Petersburg
  • St. Joseph's Cancer Institute at St. Joseph's Hospital — Tampa

California

  • Childrens Hospital Los Angeles — Los Angeles
  • Southern California Permanente Medical Group — Los Angeles
  • Children's Hospital Central California — Madera
  • Lucile Packard Children's Hospital at Stanford University Medical Center — Palo Alto
  • Rady Children's Hospital - San Diego — San Diego
  • UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco

Connecticut

  • Connecticut Children's Medical Center — Hartford
  • Yale Cancer Center — New Haven

Alabama

  • UAB Comprehensive Cancer Center — Birmingham

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock

Delaware

  • Alfred I. duPont Hospital for Children — Wilmington

Hawaii

  • Cancer Research Center of Hawaii — Honolulu

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2007-05
Est. Completion 2017-02-28

Sponsor

Children's Oncology Group

318 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00458887

The ClinicalTrials.gov registry entry for NCT00458887 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 318 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention — of which management of therapy complications is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00458887 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Florida, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00458887 about?

NCT00458887 is a clinical study titled "Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin". RATIONALE: New ways to find out about hearing loss after treatment with chemotherapy may improve the ability to plan cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is assessing ear damage in young cancer patients treated with cisplatin.

What is the current status of trial NCT00458887?

This trial is currently completed. The enrollment target is 301 participants. The study started on 2007-05. Estimated completion is 2017-02-28.

What conditions does trial NCT00458887 study?

This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific, Ototoxicity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00458887?

The interventions under investigation include: management of therapy complications (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00458887?

This trial is sponsored by Children's Oncology Group, which has 318 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00458887 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial